RESUMEN
Seven novel tertiary alcohol containing linear HIV-1 protease inhibitors (PIs), decorated at the para position of the benzyl group in the P1' side with (hetero)aromatic moieties, were synthesized and biologically evaluated. To study the inhibition and antiviral activity effect of P1-P3 macrocyclization, 14- and 15-membered macrocyclic PIs were prepared by ring-closing metathesis of the corresponding linear PIs. The macrocycles were more active than the linear precursors and compound 10f, with a 2-thiazolyl group in the P1' position, was the most potent PI of this new series (Ki 2.2 nM, EC50 0.2 µM). Co-crystallized complexes of both linear and macrocyclic PIs with the HIV-1 protease enzyme were prepared and analyzed.
Asunto(s)
Alcoholes/síntesis química , Inhibidores de la Proteasa del VIH/síntesis química , Proteasa del VIH/química , VIH-1/efectos de los fármacos , Hidrazinas/síntesis química , Compuestos Macrocíclicos/síntesis química , Péptidos Cíclicos/síntesis química , Alcoholes/química , Alcoholes/farmacología , Línea Celular , Permeabilidad de la Membrana Celular , Cristalografía por Rayos X , Proteasa del VIH/metabolismo , Inhibidores de la Proteasa del VIH/química , Inhibidores de la Proteasa del VIH/farmacología , Humanos , Hidrazinas/química , Hidrazinas/farmacología , Compuestos Macrocíclicos/química , Compuestos Macrocíclicos/farmacología , Modelos Moleculares , Péptidos Cíclicos/química , Péptidos Cíclicos/farmacología , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
To study P1-P3 macrocyclizations of previously reported tertiary-alcohol-comprising HIV-1 protease inhibitors (PIs), three new 14- and 15-member macrocyclic PIs were designed, synthesized by ring-closing metathesis, and evaluated alongside with 10 novel linear PIs. Cocrystallized complexes of the macrocyclic PIs and the HIV-1 protease are presented, analyzed, and discussed. The macrocyclic structures exhibited higher activities than the linear precursors with Ki and EC50 values down to 3.1 nM and 0.37 µM, respectively.
Asunto(s)
Alcoholes/química , Diseño de Fármacos , Inhibidores de la Proteasa del VIH/síntesis química , Inhibidores de la Proteasa del VIH/farmacología , Proteasa del VIH/metabolismo , Compuestos Macrocíclicos/síntesis química , Compuestos Macrocíclicos/farmacología , Técnicas de Química Sintética , Cristalografía por Rayos X , Proteasa del VIH/química , Inhibidores de la Proteasa del VIH/química , Compuestos Macrocíclicos/química , Modelos Moleculares , Conformación ProteicaRESUMEN
The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1-22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe-Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing a heterocyclic 6-methoxy-3-pyridinyl or a 6-(dimethylamino)-3-pyridinyl moiety (R(3)) at the para-position of the P1' benzyl fragment generated compounds with antiviral potency in the low single digit nanomolar range. Halogenation or alkylation of the metabolic hot spots on the various aromatic rings resulted in PIs with high stability against degradation in human liver microsomes and low plasma clearance in rats. Replacing the chromanolamine moiety (R(1)) in the P2 protease binding site by a cyclopentanolamine or a cyclohexanolamine derivative provided a series of high clearance PIs (16-22) with EC(50)s on wild-type HIV-1 in the range of 0.8-1.8 nM. PIs 18 and 22, formulated as nanosuspensions, showed gradual but sustained and complete release from the injection site over two months in rats, and were therefore identified as interesting candidates for a LA injectable drug application for treating HIV/AIDS.
Asunto(s)
Carbamatos/síntesis química , Dipéptidos/síntesis química , Diseño de Fármacos , Inhibidores de la Proteasa del VIH/síntesis química , Proteasa del VIH/química , VIH-1/enzimología , Piridinas/síntesis química , Alquilación , Animales , Carbamatos/química , Carbamatos/farmacocinética , Dipéptidos/química , Dipéptidos/farmacocinética , Proteasa del VIH/metabolismo , Inhibidores de la Proteasa del VIH/química , Inhibidores de la Proteasa del VIH/farmacocinética , Semivida , Halogenación , Humanos , Microsomas Hepáticos/metabolismo , Piridinas/química , Piridinas/farmacocinética , Ratas , Relación Estructura-ActividadRESUMEN
In an effort to identify a new class of druglike HIV-1 protease inhibitors, four different stereopure ß-hydroxy γ-lactam-containing inhibitors have been synthesized, biologically evaluated, and cocrystallized. The impact of the tether length of the central spacer (two or three carbons) was also investigated. A compound with a shorter tether and (3R,4S) absolute configuration exhibited high activity with a K(i) of 2.1 nM and an EC(50) of 0.64 µM. Further optimization by decoration of the P1' side chain furnished an even more potent HIV-1 protease inhibitor (K(i) = 0.8 nM, EC(50) = 0.04 µM). According to X-ray analysis, the new class of inhibitors did not fully succeed in forming two symmetric hydrogen bonds to the catalytic aspartates. The crystal structures of the complexes further explain the difference in potency between the shorter inhibitors (two-carbon spacer) and the longer inhibitors (three-carbon spacer).
Asunto(s)
Inhibidores de la Proteasa del VIH/química , Proteasa del VIH/química , Lactamas/química , Células CACO-2 , Permeabilidad de la Membrana Celular , Cristalografía por Rayos X , Proteasa del VIH/metabolismo , Inhibidores de la Proteasa del VIH/síntesis química , Inhibidores de la Proteasa del VIH/farmacología , VIH-1/efectos de los fármacos , VIH-1/enzimología , Humanos , Lactamas/síntesis química , Lactamas/farmacología , Modelos Moleculares , Estructura Molecular , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
By a small modification in the core structure of the previously reported series of HIV-1 protease inhibitors that encompasses a tertiary alcohol as part of the transition-state mimicking scaffold, up to 56 times more potent compounds were obtained exhibiting EC(50) values down to 3 nM. Three of the inhibitors also displayed excellent activity against selected resistant isolates of HIV-1. The synthesis of 25 new and optically pure HIV-1 protease inhibitors is reported, along with methods for elongation of the inhibitor P1' side chain using microwave-accelerated, palladium-catalyzed cross-coupling reactions, the biological evaluation, and X-ray data obtained from one of the most potent analogues cocrystallized with both the wild type and the L63P, V82T, I84 V mutant of the HIV-1 protease.
Asunto(s)
Alcoholes/síntesis química , Antivirales/química , Antivirales/síntesis química , Inhibidores de la Proteasa del VIH/síntesis química , Alcoholes/farmacología , Antivirales/farmacología , Cristalografía por Rayos X , Proteasa del VIH/genética , Inhibidores de la Proteasa del VIH/química , Inhibidores de la Proteasa del VIH/farmacología , VIH-1/genética , Concentración 50 Inhibidora , Imitación Molecular , Mutación MissenseRESUMEN
The synthesis and SAR of HIV-1 protease inhibitors containing novel P2 structural elements are presented. The inhibitors were designed having hydrogen bond accepting P2 substituents to probe potential favorable interactions to Asp-29/Asp-30 of the HIV-1 protease backbone utilizing inhibitor 3 as a model template. Several inhibitors were synthesized from an L-Val methyl amide P2 motif by appending hydrogen bonding moieties from either the isopropyl side-chain or from the methyl amide portion. The most promising inhibitors 4a and 4e displayed Ki values of 1.0 nM and 0.7 nM respectively and EC50 values in the MT4 cell-based assay of 0.17 microM and 0.33 microM respectively, a slight loss in potency compared to lead inhibitor 3. These inhibitors were also tested against an HIV protease inhibitor resistant strain carrying the M46I, V82F, and I84V mutations. Inhibitors 4a and 4e displayed a 3 and 4 fold change respectively compared with HIV wild type, whereas lead inhibitor 3 showed a higher 9 fold change. This study further demonstrate the chemical tractability of the approach where various P2 substituents can be introduced in just one chemical step from lactone 21 enabling facile modifications of the overall properties in this inhibitor class.
Asunto(s)
Alcoholes/química , Alcoholes/farmacología , Diseño de Fármacos , Inhibidores de la Proteasa del VIH/química , Inhibidores de la Proteasa del VIH/farmacología , Proteasa del VIH/metabolismo , Alcoholes/síntesis química , Alcoholes/metabolismo , Animales , Línea Celular , Farmacorresistencia Viral , Proteasa del VIH/química , Inhibidores de la Proteasa del VIH/síntesis química , Inhibidores de la Proteasa del VIH/metabolismo , Modelos Moleculares , Permeabilidad , Conformación Proteica , Relación Estructura-ActividadRESUMEN
A human matrix metalloproteinase (MMP) hydroxamic acid inhibitor (CGS27023A) was cross-docked into 15 MMP-12, MMP-13, MMP-9, and MMP-1 cocrystal structures. The aim was to validate a fast protocol for ligand binding conformation elucidation and to probe the feasibility of using inhibitor-protein NMR contacts to dock an inhibitor into related MMP crystal structures. Such an approach avoids full NMR structure elucidation, saving both spectrometer- and analysis time. We report here that for the studied MMPs, one can obtain docking results well within 1 A compared to the corresponding reference X-ray structure, using backbone amide contacts only. From the perspective of the pharmaceutical industry, these results are relevant for the binding studies of inhibitor series to a common target and have the potential advantage of obtaining information on protein-inhibitor complexes that are difficult to crystallize.
Asunto(s)
Espectroscopía de Resonancia Magnética/métodos , Metaloproteasas/química , Cristalografía por Rayos X , Ligandos , Modelos Moleculares , Estructura MolecularRESUMEN
Small inhibitors of matrix metalloproteinase 12 (MMP-12) have been identified with a biosensor-based screening strategy and a specifically designed fragment library. The interaction between fragments and three variants of the target and a reference protein with an active-site zinc ion was measured continuously by surface plasmon resonance. The developed experimental design overcame the inherent instability of MMP-12 and allowed the identification of fragments that interacted specifically with the active-site of MMP-12 but not with the reference protein. The interaction with MMP-12 for selected compounds were analyzed for concentration dependence and saturability. Compounds interacting distinctly with the target were further evaluated by an activity-based assay, verifying MMP-12 inhibition. Two effective inhibitors were identified, and the compound with highest affinity was confirmed to be a competitive inhibitor with an IC50 of 290 nM and a ligand efficiency of 0.7 kcal/mol heavy atom. This procedure integrates selectivity and binding site identification into the screening procedure and does not require structure determination.
Asunto(s)
Técnicas Biosensibles , Diseño de Fármacos , Metaloproteinasa 12 de la Matriz/química , Inhibidores de la Metaloproteinasa de la Matriz , Bibliotecas de Moléculas Pequeñas , Bencimidazoles/química , Benzoxazinas/química , Sitios de Unión , Anhidrasa Carbónica II/química , Inhibidores de Anhidrasa Carbónica/química , Cationes Bivalentes , Ácidos Hidroxámicos , Indoles/química , Cinética , Ligandos , Unión Proteica , Quinolinas/química , Resonancia por Plasmón de Superficie , Termodinámica , Tiazoles/química , Zinc/químicaRESUMEN
A new generation of HIV-1 protease inhibitors encompassing a tertiary-alcohol-based transition-state mimic has been developed. By elongation of the core structure of recently reported inhibitors with two carbon atoms and by varying the P1' group of the compounds, efficient inhibitors were obtained with Ki down to 2.3 nM and EC50 down to 0.17 microM. Two inhibitor-enzyme X-ray structures are reported.
Asunto(s)
Alcoholes/química , Carbamatos/síntesis química , Inhibidores de la Proteasa del VIH/síntesis química , VIH-1/efectos de los fármacos , Hidrazinas/síntesis química , Modelos Moleculares , Sitios de Unión , Carbamatos/química , Carbamatos/farmacología , Línea Celular , Cristalografía por Rayos X , Inhibidores de la Proteasa del VIH/química , Inhibidores de la Proteasa del VIH/farmacología , VIH-1/enzimología , Humanos , Hidrazinas/química , Hidrazinas/farmacología , Imidazoles/síntesis química , Imidazoles/química , Imidazoles/farmacología , Imitación Molecular , Oxadiazoles/síntesis química , Oxadiazoles/química , Oxadiazoles/farmacología , Piridinas/síntesis química , Piridinas/química , Piridinas/farmacología , EstereoisomerismoRESUMEN
Several highly potent novel HCV NS3 protease inhibitors have been developed from two inhibitor series containing either a P2 trisubstituted macrocyclic cyclopentane- or a P2 cyclopentene dicarboxylic acid moiety as surrogates for the widely used N-acyl-(4R)-hydroxyproline in the P2 position. These inhibitors were optimized for anti HCV activities through examination of different ring sizes in the macrocyclic systems and further by exploring the effect of P4 substituent removal on potency. The target molecules were synthesized from readily available starting materials, furnishing the inhibitor compounds in good overall yields. It was found that the 14-membered ring system was the most potent in these two series and that the corresponding 13-, 15-, and 16-membered macrocyclic rings delivered less potent inhibitors. Moreover, the corresponding P1 acylsulfonamides had superior potencies over the corresponding P1 carboxylic acids. It is noteworthy that it has been possible to develop highly potent HCV protease inhibitors that altogether lack the P4 substituent. Thus the most potent inhibitor described in this work, inhibitor 20, displays a K(i) value of 0.41 nM and an EC(50) value of 9 nM in the subgenomic HCV replicon cell model on genotype 1b. To the best of our knowledge this is the first example described in the literature of a HCV protease inhibitor displaying high potency in the replicon assay and lacking the P4 substituent, a finding which should facilitate the development of orally active small molecule inhibitors against the HCV protease.
Asunto(s)
Ciclopentanos/farmacología , Inhibidores Enzimáticos/farmacología , Compuestos Macrocíclicos/farmacología , Proteínas no Estructurales Virales/antagonistas & inhibidores , Sitios de Unión , Línea Celular , Cristalografía por Rayos X , Ciclización , Ciclopentanos/síntesis química , Ciclopentanos/química , Ácidos Dicarboxílicos/química , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Hepacivirus/enzimología , Humanos , Compuestos Macrocíclicos/síntesis química , Compuestos Macrocíclicos/química , Modelos Moleculares , Conformación Molecular , Estereoisomerismo , Relación Estructura-Actividad , Replicación Viral/efectos de los fármacosRESUMEN
A short synthetic protocol leading to HIV-1 protease inhibitors with a tertiary alcohol based transition-state mimicking unit and different P2 side chains has been developed.
Asunto(s)
Alcoholes/química , Inhibidores de la Proteasa del VIH/química , VIH-1/enzimología , Cristalografía por Rayos XRESUMEN
Two series of P1'-extended HIV-1 protease inhibitors comprising a tertiary alcohol in the transition-state mimic exhibiting Ki values ranging from 2.1 to 93 nM have been synthesized. Microwave-accelerated palladium-catalyzed cross-couplings were utilized to rapidly optimize the P1' side chain. High cellular antiviral potencies were encountered when the P1' benzyl group was elongated with a 3- or 4-pyridyl substituent (EC50 = 0.18-0.22 microM). X-ray crystallographic data were obtained for three inhibitors cocrystallized with the enzyme.
Asunto(s)
Alcoholes/síntesis química , Inhibidores de la Proteasa del VIH/síntesis química , Proteasa del VIH/química , Indanos/síntesis química , Alcoholes/química , Alcoholes/farmacología , Sitios de Unión , Catálisis , Línea Celular , Cristalografía por Rayos X , Inhibidores de la Proteasa del VIH/química , Inhibidores de la Proteasa del VIH/farmacología , VIH-1/efectos de los fármacos , Humanos , Enlace de Hidrógeno , Indanos/química , Indanos/farmacología , Microondas , Imitación Molecular , PaladioRESUMEN
Novel HIV-1 protease inhibitors encompassing a tertiary alcohol as part of the transition-state mimicking unit have been synthesized. Variation of the P1'-P3' residues and alteration of the tertiary alcohol absolute stereochemistry afforded 10 inhibitors. High potencies for the compounds with (S)-configuration at the carbon carrying the tertiary hydroxyl group were achieved with Ki values down to 2.4 nM. X-ray crystallographic data for a representative compound in complex with HIV-1 protease are presented.